Ovid Therapeutics (NASDAQ:OVID) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Ovid Therapeutics (NASDAQ:OVID – Free Report) from a hold rating to a sell rating in a research note published on Saturday,Wall Street Zen reports.

Several other research analysts have also commented on the stock. HC Wainwright lifted their price target on shares of Ovid Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a report on Friday, September 11th. Guggenheim assumed coverage on shares of Ovid Therapeutics in a research note on Tuesday, October 6th. They set a “buy” rating and a $7.00 price objective on the stock. Oppenheimer raised their target price on shares of Ovid Therapeutics from $7.00 to $9.00 and gave the stock an “outperform” rating in a report on Monday, August 3rd. UBS Group reissued a “buy” rating on shares of Ovid Therapeutics in a report on Friday, September 11th. Finally, Cantor Fitzgerald initiated coverage on Ovid Therapeutics in a research note on Friday, October 9th. They issued an “overweight” rating for the company. Eleven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $6.12.

View Our Latest Analysis on Ovid Therapeutics

Ovid Therapeutics Stock Performance

Ovid Therapeutics stock opened at $2.40 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 11.97 and a quick ratio of 12.39. Ovid Therapeutics has a 12 month low of $1.21 and a 12 month high of $3.11. The company has a fifty day moving average price of $2.50 and a two-hundred day moving average price of $2.40. The company has a market cap of $452.95 million, a PE ratio of -10.00 and a beta of 0.24.

Ovid Therapeutics (NASDAQ:OVID – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Research analysts expect that Ovid Therapeutics will post -0.39 earnings per share for the current year.

Institutional Investors Weigh In On Ovid Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Jupiter Topco LLC bought a new position in shares of Ovid Therapeutics during the second quarter worth about $55,898,000. BlackRock Inc. bought a new stake in Ovid Therapeutics in the 2nd quarter valued at about $29,115,000. Janus Henderson Group PLC bought a new stake in Ovid Therapeutics in the 1st quarter valued at about $23,732,000. Affinity Asset Advisors LLC lifted its position in Ovid Therapeutics by 48.8% in the 1st quarter. Affinity Asset Advisors LLC now owns 10,636,318 shares of the company’s stock valued at $23,613,000 after purchasing an additional 3,486,318 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in Ovid Therapeutics during the 2nd quarter valued at about $19,953,000. 72.24% of the stock is currently owned by institutional investors.

Ovid Therapeutics Company Profile

(Get Free Report)

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for epilepsies and other neurological disorders. Its work targets conditions with significant unmet treatment needs, including rare and difficult-to-treat seizure disorders. The company’s lead development program, OV329, is an investigational GABA aminotransferase inhibitor being studied as a potential treatment for seizures, including infantile spasms and focal-onset seizures. Ovid’s pipeline and research programs may change as clinical development progresses.

Recommended Stories

Analyst Recommendations for Ovid Therapeutics (NASDAQ:OVID)

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.